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Strengths and limitations of this study
 ► Matching of single donor with each patient—this 
will allow detailed exploration of donor character-
istics associated with a favourable patient response.
 ► Intensive faecal microbiota transplant (FMT) treat-
ment regimen—shown to be a major contributing 
factor in clinical response to FMT.
 ► Assessment of mechanistic outcomes and donor di-
et—this will help in understanding the mechanisms 
associated with response to FMT.
 ► Qualitative data from clinicians and patients inform-
ing the potential future randomised controlled trial 
(RCT).
 ► This study is limited to assessing the feasibility of an 
RCT and the best route of FMT delivery in ulcerative 
colitis (UC) patients. The assessment of the efficacy 
of FMT in achieving and maintaining remission for 
patients with UC needs to be tested in a future full- 
scale RCT.
AbStrACt
Introduction Imbalance of the gut microbiome is key 
to the pathogenesis of ulcerative colitis (UC). Faecal 
microbiota transplant (FMT) is the transfer of homogenised 
and filtered faeces from a healthy individual to the 
gastrointestinal tract of a patient with disease. Published 
datasets show a positive signal for the use of FMT to 
treat UC, but the optimal route and dose of FMT remain 
unanswered.
Methods and analysis This prospective, multi- centre 
open- label, randomised pilot study will assess two 
possible routes of FMT delivery, via the nasogastric 
(NG) route or by delivery to the COLON, in 30 patients 
with active UC recruited from three sites in the UK. 
Stool will be collected from healthy screened donors, 
processed, frozen and stored under a Medicines 
and Healthcare products Regulatory Agency (MHRA) 
“specials” manufacturing licence held at the University of 
Birmingham Microbiome Treatment Centre. Thawed FMT 
samples will be administered to patients either via eight 
nasogastric infusions given initially over 4 days starting 
on the day of randomisation, and then again for 4 days 
in week 4 for foregut delivery (total of 240 g of stool) or 
via one colonoscopic infusion followed by seven weekly 
enemas according to the hindgut protocol (total of 360 g 
of stool). Patients will be followed up weekly for 8 weeks, 
and then at 12 weeks. The aims of this pilot study are 
(1) to determine which FMT administration route (NG or 
COLON) should be investigated in a randomised double- 
blind, placebo- controlled trial and (2) to determine if a 
full randomised controlled trial is feasible. The primary 
outcome will be a composite assessment of both 
qualitative and quantitative data based on efficacy (clinical 
response), acceptability and safety. At the end of the pilot 
study, decisions will be made regarding the feasibility of a 
full randomised double- blind, placebo- controlled trial and, 
if deemed feasible, which route of administration should 
be used in such a study.
Ethics and dissemination Ethical approval for this study 
has been obtained from the East Midlands- Nottingham 
Research Ethics Committee (REC 17/EM/0274). At the 
end of the study, findings will be reported at national and 
international gastroenterology meetings and published in 
peer- reviewed journals.
trial registration number ISRCTN74072945
IntroduCtIon
In the inflammatory bowel diseases (IBDs), 
Crohn’s disease (CD) and ulcerative colitis 
(UC), there is imbalance or 'dysbiosis' of the 
gut microbiota compared with the healthy 
bowel, with individuals having IBD showing 
reduced bacterial diversity compared with 
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healthy individuals.1 2Indeed, the currently accepted para-
digm concerning the pathogenesis of IBD involves an aber-
rant immunological response to the intestinal microbiota 
in a genetically susceptible host.3 Whether the observed 
dysbiosis represents ‘cause’ or ‘effect’ remains unanswered. 
Faecal microbiota transplant (FMT) is the infusion of a 
faecal suspension from a healthy donor into the gastrointes-
tinal tract of a patient with disease, and there is interest in 
the potential of this technique for modifying the gut micro-
biome as a potential treatment for IBD.4
Since the first descriptions of CD and UC at the beginning 
of the 20th century, it has been strongly suspected that the 
gut microbiota may have a defining role in the pathogen-
esis of IBD.5 Early culture- based studies underestimated the 
complexity of the microbiota, and were hampered by various 
culture biases and the challenge of enumerating fastidious 
bacteria with complex growth conditions. With the advent 
of cheap high- throughput genetic sequencing techniques 
allied with complex bioinformatics capability, there has been 
a revolution in our understanding of the composition and 
function of the colonic microbiome. As a result of studies 
on the microbiome both in patients with IBD and animal 
models, we know that patients with IBD (either CD or UC) 
have, at the phylum level, a reduction in Firmicutes and a 
relative increase in Proteobacteria.2 6
Accumulating data suggest that alteration in the gut 
microbiome plays a central role in driving UC; datasets 
highlighting the importance of Roseburia hominis,7 Faecali-
bacterium prausnitzii8 and Akkermansia muciniphila9 mediating 
anti- inflammatory responses in UC have been published. 
Attempts to alter the microbiome with probiotics, while 
disappointing in CD, have shown some promise in UC.10 11 
Since the first exploratory use of FMT to treat UC in 1989,12 
numerous case series have been published demonstrating 
encouraging efficacy signals.13 This has led to investigators 
testing FMT as a treatment for UC and to date there have 
been four randomised controlled trials (RCTs) of FMT 
for the treatment of UC.14 The first was a trial of fresh and 
frozen enemas which were delivered weekly for 6 weeks, 
water being used as placebo.15 There was a significant 
increase in remission at the primary endpoint in the active 
versus placebo arm. In the second study, fresh FMT by naso-
jejunal delivery was used and autologous stool was used as 
placebo.16 Although the results favoured active treatment, 
they were not statistically significant. The last two RCTs 
were reported in 201717 18and both used frozen FMT from 
pooled donors and involved intensive treatment regimens. 
Both achieved statistically significant results in favour of 
active treatment, with remission rates comparing active and 
placebo of 32% vs 9%18 and 27% vs 8%, respectively.17
As a result of this recent work, there is great interest 
in FMT as a possible treatment for UC, but the optimal 
route of delivery remains unknown. Before we can 
undertake a full- scale double- blind RCT of FMT versus 
placebo, we need to undertake a pilot study to determine 
the optimum route of FMT delivery and assess the feasi-
bility (recruitment, protocol adherence) of undertaking 
a trial of FMT in UC. In this pilot study, we will compare 
nasogastric (NG) versus colonoscopic (COLON) delivery 
of FMT, using an intensive treatment regimen, in patients 
with active UC to investigate the optimum route of FMT 
delivery for the treatment of UC. We will assess the 
effectiveness and acceptability of the two routes of FMT 
delivery, and whether FMT by either NG or COLON is 
suitable to take forward to a full RCT against placebo, 
and whether such a trial is feasible. Here we describe the 
protocol for the STOP- Colitis pilot study.
MEthodS And AnAlySIS
Study design
A prospective, multi- centre open- label, randomised pilot 
study to assess two possible routes of FMT delivery for 
the treatment of UC. Thirty patients with active UC will 
be randomised to receive FMT via either the NG route 
or by direct delivery to the COLON. Patients will be 
recruited from three hospitals in the UK (Queen Eliza-
beth Hospital, Birmingham; St Mark’s Hospital, London 
and Glasgow Royal Infirmary).
At the end of the pilot study, the data will be reviewed by 
an Independent Oversight Committee (IOC), consisting 
of two consultant gastroenterologists and a professor of 
medical statistics and clinical trials, who, according to the 
prespecified STOP/GO criteria (see Analysis of outcome 
measures below) will decide (1) which route of FMT 
administration (NG or COLON) is most appropriate to 
investigate in the full randomised double- blind, placebo- 
controlled trial and (2) whether it is feasible to proceed 
to the main RCT.
Sample size
As this is a pilot study, no formal sample size calculation 
was undertaken as the study is not designed or powered 
to detect a statistically significant difference in efficacy 
between the two FMT methods of delivery. The recruit-
ment target for this study is 30 patients.
Aims and objectives
The aims of this pilot study are as follows:
1. To determine which FMT administration route (NG 
or COLON) should be investigated in a randomised 
double- blind, placebo- controlled trial.
2. To determine whether a full RCT is feasible.
In order to achieve these aims, the pilot study has the 
following clinical (quantitative), qualitative and mecha-
nistic objectives.
Clinical objectives
To assess:
1. Whether FMT by the NG route induces clinical re-
sponse in patients with active UC.
2. Whether FMT by the COLON route induces clinical 
response in patients with active UC.
3. Tolerability and safety.
4. Which route of FMT delivery (if any) is suitable to in-
vestigate in a RCT.
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Qualitative objectives
To assess:
1. Patient acceptability of FMT (NG).
2. Patient acceptability of FMT (COLON).
Mechanistic objectives
To assess:
1. Whether FMT by either route is associated with a 
change in faecal calprotectin as a surrogate marker of 
colonic inflammation.
2. Changes in the colonic microbiome and metabolome 
(short chain fatty acids (SCFA)) induced by FMT via 
each route.
3. Reduction in C- reactive protein (CRP).
Other objectives
1. Effect of diet (donors) on microbiome.
2. Effect of time from stool donation to treatment on suc-
cess of FMT.
outcome measures
The primary outcome will be a composite assessment of 
both qualitative and quantitative data relating to efficacy, 
acceptability, safety and mechanistic outcomes.
Clinical outcome measures
1. Clinical response (primary measure of efficacy) de-
fined as ≥3 point reduction in the full Mayo score from 
randomisation to week 8, and 30% reduction from ran-
domisation and at least one point reduction of rectal 
bleeding sub- score or an absolute rectal bleeding sub-
score of 0 or 1.
2. Time to clinical response (where clinical response is 
defined as ≥2 point reduction in partial Mayo).
3. Clinical remission at week 8 (full Mayo score of ≤2, 
with no subscore >1).
4. Participant’s weight at weeks 8 and 12.
5. Quality of Life (QoL) using the generic Short- Form 36 
(SF-36) and the disease specific Inflammatory Bowel 
Disease Questionnaire (IBDQ) at weeks 8 and 12.
6. Adherence to FMT.
7. Adverse events (AE) and serious adverse events (SAE).
Qualitative data
Patient acceptability will be assessed through qualitative 
research interviews. During these interviews, patients from 
both groups will be asked about their perspectives and expe-
rience of FMT during the pilot trial, including receiving the 
intervention, recovering from the intervention and their 
symptoms and QoL. Further examples of interview ques-
tions can be found in the online supplementary file 1.
Mechanistic outcome measures
1. Faecal calprotectin.
2. Measures of microbiome (faecal and mucosal)—spe-
cifically shifts in alpha diversity following FMT.
3. Mucosal healing.
4. Urinary metabolome (SCFA).
5. CRP.
Other outcome measures
1. Association between the donors’ and recipients’ di-
etary profile and microbiome.
2. Time, that is, number of days, from donor stool pro-
cessing to treatment for association between efficacy 
and freezer life of FMT.
donor sample acquisition and processing
Donors will be recruited following advertisement from 
healthy unrelated anonymous individuals living in 
Birmingham. We are excluding healthcare workers due to 
their potential exposure to microbes affecting the micro-
biome. Donors must be ≥18 and<50 years of age, have a 
normal morning bowel habit, have a normal body mass 
index (≥18.5 and ≤25), be non- smokers (not smoked for 
at least 12 months) and have no recent history of diar-
rhoea or rectal bleeding. Potential donors will undergo 
rigorous screening using a health- screening question-
naire. Those who are eligible following this screening will 
be consented for the donation process and have blood 
and faecal samples taken to test for transmissible patho-
gens in accordance with UK, American Gastroenterology 
Association (AGA) and European guidelines.19–21Indi-
viduals who pass the screening process will be invited to 
donate morning faecal samples for 10 days and to deliver 
these for processing within 6 hours of defaecation. At first 
donation, they will also be asked to complete the EPIC- 
Norfolk food frequency questionnaire.22
Donations will be processed and stored under an 
MHRA manufacturing licence at the University of 
Birmingham Microbiome Treatment Centre. Stool 
collection and processing were performed under aerobic 
conditions. Donations will be prepared in saline with 10% 
glycerol added as a cytoprotectant. Samples will then be 
stored frozen at −80°C for up to 24 weeks. Samples will 
be dispatched for use at each site as required. An aliquot 
from each donated sample will be kept for analysis in the 
event of AEs occurring as a result of FMT and samples 
from each donation period will be sent for genetic 
sequencing and metabolic analysis. At the end of each 
10- day donation period, donors will receive financial 
compensation and will undergo an exit health question-
naire and be asked to provide a further stool sample to 
test for pathogens. Further information on the donor 
sample processing will be present in the protocol and 
a laboratory standard operating procedure (SOP) for 
donor preparation (available on request).
Participants
Inclusion criteria
1. Adult patients (aged between 16 and 70 years) with 
clinically confirmed UC for at least 12 weeks prior to 
the screening visit.
2. Partial Mayo score of ≥4 and≤8 despite stable disease 
maintenance treatment with 5- aminosalicylates with or 
without immunomodulators, or on no treatment.
3. Rectal bleeding subscore of ≥1 on the partial Mayo;.
4. Able to give written, signed informed consent.
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Exclusion criteria
1. Stool positive for Clostridium difficile or infection by ei-
ther PCR or ELISA.
2. Positive for Hepatitis A/B/C and/or HIV infection.
3. Antibiotics in the preceding 12 weeks prior to date of 
the screening visit.
4. Systemic/topical steroids in the preceding 2 weeks pri-
or to the date of the screening visit.
5. Biologics in the preceding 12 weeks prior to the date 
of screening visit.
6. Commercial probiotics and prebiotics in the preced-
ing 12 weeks prior to the date of the screening visit.
7. On oral nutritional supplements or enteral/parenteral 
nutrition in the preceding 4 weeks prior to the date of 
the screening visit.
8. Pregnant or lactating.
9. Not willing to take appropriate contraceptive measures 
to prevent pregnancy during trial participation.
Participant enrolment
Potentially eligible patients who express an interest in 
participating in the trial will be consented via a two- stage 
consent process. Participant information sheets will be 
provided to facilitate the consent process.
Registration and screening visit
The first stage will involve consent for trial- specific 
screening activities, and consent to collect stool and urine 
samples for the mechanistic substudies. Patients will 
undergo basic physiological assessments (pulse, blood 
pressure, temperature, height and weight) and baseline 
blood tests. They will be provided with a diary to record 
bowel symptoms (so that the partial Mayo score can be 
calculated at the randomisation visit), stool sample kits 
and bowel preparation kits (Moviprep). They will be asked 
to return the C. difficile stool sample as soon as possible, so 
that the result is available prior to the randomisation visit.
Following the screening visit, the qualitative researcher 
will arrange for an interview with the patient to take place 
prior to their randomisation visit (see Randomisation visit 
below). The research team at the hospital will contact the 
patient to notify them of their stool result. If they tested 
negative for C. difficile, they will be invited to attend the 
randomisation visit. Instructions will be given on when 
to take the bowel preparation, and they will be asked to 
collect a stool sample on the same day prior to taking the 
bowel preparation, which they will bring to the randomi-
sation visit.
Randomisation visit
The second stage is consent for entry into the trial. 
Following confirmation of all eligibility criteria and 
consent to randomisation, basic physiological assessments 
will be undertaken, blood test results will be checked, 
a urine sample will be taken for pregnancy testing in 
women and metabolomics and the partial Mayo score 
will be calculated from diaries. The patient will be asked 
to complete the baseline QoL questionnaires—IBDQ 
and SF-36. All patients will have a colonoscopy to assess 
disease (done after randomisation), so that a full Mayo 
score can be calculated, and to collect mucosal biopsies.
randomisation
Patients will be randomised at the level of the individual 
in a 1:1 ratio to either NG or COLON delivery of FMT. 
Randomisation will be provided by a computer- generated 
program at the Birmingham Clinical Trials Unit. A mini-
misation algorithm will be used to ensure balance in the 
treatment allocation over the following variables:
1. Partial Mayo score (4–5 or 6–8).
2. Current smoking status (current smoker: yes or no 
(not smoked for the past 12 months)).
A ‘random element’ will be included in the minimi-
sation algorithm, so that each patient has a probability 
(unspecified here), of being randomised to the opposite 
treatment that they would have otherwise received.
Interventions
Before the initial FMT treatment, all patients will receive 
standard bowel preparation: 2 L of reconstituted Movi-
prep solution within the 24 hours prior to procedure.
NG treatment
Patients randomised to NG treatment will be pretreated 
with a proton pump inhibitor (lansoprazole 30 mg) and 
a prokinetic agent (domperidone 10 mg) at least 30 min 
prior to each FMT infusion to reduce gastric acid secre-
tion and prevent the risk of gastro- oesophageal regur-
gitation. Naso- gastric tubes (NGTs) will be positioned 
and checked for correct position as per local protocol. 
Following thawing at room temperature, 50 mL thawed 
FMT containing 30 g faeces will be infused. Following 
the first treatment, patients will return for the next 3 
days for further treatment following an overnight fast. 
It will be the individual’s choice whether they wish to 
retain the NGT for the 4- day treatment course or have 
the tube removed and repassed every day. On the last day 
of treatment, the NGT will be removed to be replaced for 
the second course of treatment. At week 4, patients will 
return for a further four FMT infusions over 4 consecu-
tive days following a fast from midnight.
In summary, patients will receive 30 g FMT in 50 mL 
aliquots for NG administration each day for 4 days at the 
start of the trial (starting on the day of randomisation), 
and then again for 4 days in week 4 (total FMT dose 240 
g).
COLON treatment
Patients randomised to COLON treatment will receive a 
thawed 250 mL aliquot of FMT (containing 150 g faeces) 
on the day of randomisation. This will be delivered to the 
colon using a spray catheter, with 125 mL sprayed into 
the caecum to treat the right side of the bowel and the 
remaining 125 mL sprayed directly onto the rest of the 
colon. Following treatment, patients will receive a single 
dose of loperamide. Patients will return on a weekly basis 
to receive 100 mL enema up to week 7 containing 50 mL 
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of saline and 30 g faeces, followed by loperamide each 
time.
In summary, patients will receive 150 g of stool in 250 
mL for colonic administration on the day of randomisa-
tion followed by 30 g of stool in 100 mL in normal saline 
for administration by enema for 7 weeks (total FMT dose 
360 g).
data collection
All patients will be followed weekly up to week 8, and then 
again at week 12. At each visit, the partial Mayo score will 
be calculated from the patient diaries, and medication 
use and any adverse events occurring will be recorded. 
Stool samples will be collected at weeks 2, 4, 6, 8 and 12, 
and blood samples will be taken for CRP assessment at 
weeks 4, 6 and 8. At weeks 8 and 12, physiological data, 
a urine sample and the SF-36 and IBDQ QoL question-
naires will also be collected. At week 8, a flexible sigmoid-
oscopy will be undertaken to calculate the full Mayo score 
(see online supplementary figure 1).
timelines
We completed recruitment into this pilot study in April 
2019. Data collection will be completed by July 2019 and 
analysis of the data will commence in August 2019.
Qualitative research: patient and clinician experience and 
acceptability of FMt and trial processes
A comparison of the acceptability of the two routes of 
FMT being used in this study is key to the outcome of 
this pilot study. A qualitative researcher will conduct 
interviews with patients participating in both arms of 
the trial. Each patient will take part in a semistructured 
interview at two time points; following the screening visit 
prior to randomisation and after the 12- week follow- up 
visit. These one- to- one interviews will take place either 
in person, by telephone or Skype, as preferred by the 
patients. The initial interview will focus on participants’ 
experience of UC and treatment to date, along with their 
understanding and expectations for FMT and the pilot 
study. A background questionnaire collecting sociode-
mographic and clinical details will also be administered. 
During the follow- up interview, patients’ actual experi-
ence within the pilot study, including that of FMT (by 
NG and COLON) and of related trial processes and 
procedures will be explored. Interviews will also gather 
data on patient perspectives regarding important impacts 
and outcomes of FMT, thus providing the opportunity to 
compare these with the outcome measures selected for 
inclusion in the pilot and (later) full RCT. Further inter-
views with patients who withdraw from FMT treatment 
early and with a small sample of patients who decline 
consent to participate following screening (should this 
happen), will provide in- depth understanding of these 
decisions. Interviews will also be conducted with staff at 
the pilot sites to review their experience of trial conduct, 
for example, the acceptability and logistics of complex 
trial procedures within clinical environments. Interviews 
schedules can be found in online supplementary file 1.
Data from this qualitative research will contribute to an 
assessment of patient and clinician experience and accept-
ability of FMT within the pilot context, and along with 
recruitment and dropout rates, and data regarding clin-
ical response, this will inform a decision about whether 
the NG or COLON route of delivery is taken forward to 
the full RCT. The qualitative data will also contribute to 
the refinement and optimisation of trial processes prior 
to the full RCT.
Analysis of qualitative data
Interviews will be recorded with the consent of partici-
pants and transcribed clean verbatim for analysis. Analysis 
will be conducted with reference to recordings, tran-
scripts and field notes taken at the time of data collec-
tion. A thematic analysis of content will be informed by 
the framework analytical approach.23 Following initial 
familiarisation with the interview data, development 
of thematic frameworks and data coding will proceed 
in an iterative manner. Data collection and analysis will 
run concurrently so that emergent analytical themes can 
inform further data collection, and in particular compar-
ative analytical questioning between patients allocated to 
NG or COLON.
Mechanistic studies
There will be two aspects to mechanistic studies under-
taken as part of this trial; non- invasive assessment of UC 
activity and assessment of patient’s microbiome response 
to FMT in comparison with that of donor microbiome at 
baseline. The study will also investigate donor diet with 
regard to baseline microbiome and treatment effect.
Non-invasive assessment of UC activity
This will be undertaken using the serum biomarker CRP 
and faecal calprotectin which will be measured using a 
standard protocol at one central laboratory in Glasgow.
Microbiome-related assays
16S ribosomal DNA sequencing and metagenomics
16S ribosomal DNA sequencing will be performed on all 
samples collected during the study: donor faeces (fresh 
and frozen from day 1 and day 10 donations), faeces 
from the recipient at baseline, weeks 2, 4, 6, 8, and 12 and 
mucosal biopsies taken from the right colon, left colon 
and rectum at baseline and from left colon and rectum 
at week 8. Together these samples will be compared 
with clinical data, and correlations found with faecal 
calprotectin, in order to find the samples most likely to 
be biologically informative as markers of disease remis-
sion. Additionally, and based on the results of the initial 
16S analysis, a shotgun metagenomics approach will 
be undertaken on around 200 selected samples to give 
insights regarding functional enrichment. For a certain 
subset of samples where additional strain resolution is 
required (eg, recovery of complete genomes of interest) 
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or linkage between extra- chromosomal elements such as 
plasmids and phages, further samples will be subject to 
long- read sequencing.
Major bacterial metabolites and metabolomics on faecal and urine 
samples
Major bacterial metabolites including faecal short and 
medium chain fatty acids previously implicated in the aeti-
ology and mucosal inflammation of IBD will be measured 
using gas chromatography and other assays as described 
previously.24–26 Analysis of SCFAs in the samples will be 
carried out on faecal samples from the donors on day 1 
and day 10 and on patients at baseline, weeks 8 and 12.
Donor assessment of dietary intake
The habitual dietary pattern of the donors will be assessed 
using the validated food frequency questionnaire as used 
in the EPIC- Norfolk study in the UK.27 Data from the 
EPIC questionnaires will be transferred to Glasgow for 
analysis. Energy, macronutrient and fibre intake will be 
estimated and expressed in nutrient ranks and quartiles 
and will also be compared against Department of Health 
recommendations and UK National Diet and Nutrition 
Survey results.
Analysis of outcome measures
The primary outcome from the pilot study will be a recom-
mendation about which route of administration (NG or 
COLON) to take forward to the main RCT, and whether 
a full RCT is feasible. The decision will be based on 
assessing the two methods of delivery using a composite 
assessment of both qualitative and quantitative data on 
efficacy using clinical response, acceptability and safety.
The primary comparison will comprise of those 
randomised to FMT by the NG route versus those 
randomised to FMT by the COLON route. All analyses 
will be based on the intention to treat principle. Data 
will be presented as summary statistics and differences 
between groups will be presented with 95% CIs from two- 
sided tests. No formal hypothesis testing will be under-
taken and no p values will be presented.
Primary outcome measures of efficacy for STOP/GO
The primary measure of efficacy for the STOP/GO is 
clinical response at week 8. The number and percentage 
of patients achieving a clinical response in the two treat-
ment groups will be reported along with the 95% CI. 
A log- binomial model will be fitted to obtain a relative 
risk and 95% CI, adjusting for the minimisation variable 
smoking status and baseline full Mayo score.
Secondary clinical outcome measures for STOP/GO
The number and percentage of patients achieving clinical 
remission in the two treatment groups will be reported. 
A log- binomial model will be fitted to obtain a relative 
risk and 95% CI, adjusting for the minimisation variables: 
smoking status and baseline partial Mayo score. Time to 
clinical response (based on the partial Mayo score) will 
be presented graphically as a Kaplan- Meier plot. A Cox 
proportional hazards regression model will be fitted to 
obtain an HR and 95% CI. Continuous data (eg, weight, 
QoL scores) will be summarised using means and SD 
presented at each time point (baseline, weeks 8 and 12). 
The week 8 and week 12 data will be compared by treat-
ment group using linear regression models with the mini-
misation variables and baseline values included in the 
model, with the mean differences and 95% CI presented.
Tolerability will be assessed quantitatively using adher-
ence. Patients will be considered adherent if they receive 
at least 70% of their intended FMT dose. The number 
and percentage of patients who are deemed adherent to 
the FMT treatment in the two treatment groups will be 
reported along with the 95% CIs.
AE and SAE data will be tabulated. For each treatment 
group, the number of AEs and the number and percentage 
of patients experiencing an AE will be reported. Data on 
SAEs will be reported in the same way.
StoP/Go guidelines
At the end of the pilot, the IOC will be convened to review 
the data. This group will make a recommendation to the 
Trial Management Group on (1) which route (if any) of 
FMT is appropriate to take forward to the full trial and 
(2) whether it is feasible to proceed to the full RCT.
To determine whether we will proceed forward to the 
main RCT, a pragmatic review of the pilot data in terms of 
assessing treatment efficacy (based on clinical response), 
tolerability and patient acceptability will be undertaken. 
STOP/GO guidelines will be used to determine whether 
to proceed forward to the main RCT, and we propose then 
to take forward the preferred method of FMT delivery 
into a randomised double- blind placebo- controlled trial 
with a clinical efficacy outcome (clinical remission).
The first STOP/GO decision will be on which route 
of FMT to take forward to the full RCT. The pilot is not 
powered to show differences in the two modes of delivery 
(NG or COLON); therefore, a decision or recommen-
dation on which route to use in the main trial requires 
expert judgement and cannot be made based on a purely 
numerical process. The following data will be reviewed by 
the IOC:
1. The proportion of patients who achieve a clinical re-
sponse following FMT by the NG route (A threshold of 
achieving a clinical response in around 40% of patients 
treated may be used. This threshold will be agreed af-
ter discussions by the Trial Management Group and 
the IOC prior to any data analysis being performed).
2. The proportion of patients who achieve a clinical re-
sponse following FMT by the COLON.
3. Whether FMT by either route is associated with a 
change in faecal calprotectin.
4. Whether FMT by either route is associated with chang-
es in the colonic microbiome and metabolome.
5. Tolerability and safety for each route.
6. Patient acceptability of FMT by the NG route through 
the qualitative interviews (including advantages and 
disadvantages of the NG route).
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7. Patient acceptability of FMT by the COLON route 
through the qualitative interviews (including advan-
tages and disadvantages of the COLON route).
Following review of the above data, whether the IOC 
can recommend a route to take forward to the main trial, 
will form the basis of the first STOP/GO decision.
1. IOC unable to recommend one particular route as nei-
ther route felt to be satisfactory. DECISION: Do not 
proceed to main RCT.
2. IOC recommends a route of FMT delivery for use in 
the main RCT. DECISION: Proceed to STOP/GO de-
cision stage 2 of pilot.
Once the route of FMT delivery has been selected, a 
second STOP/GO assessing feasibility will be used to 
determine whether to proceed to the main RCT. This will 
be based on the following:
1. That the IOC are able to recommend a route.
2. That the recruitment of the 30 patients in the pilot av-
erages 0.7 patients per week in each open site.
3. That 10 of the 15 patients in the route cohort selected 
for the main study received at least 70% of their in-
tended FMT dose. For example, 70% of the NG route 
(240 g) is 168 g, which requires the patient to receive 
at least six infusions (30 g; six out of the eight FMT 
infusions that is, patient can miss no more than two 
doses); and 70% of the COLON route (360 g) is 252 g, 
which requires the patient to receive the first infusion 
by colonoscopy (150 g) and then at least four out of 
seven of the enema infusions (30 g) that is, patient can 
miss no more than three doses.
4. That the IOC have not identified any safety concerns.
Following review of the above data, whether the IOC 
are able to recommend that a full RCT is feasible will 
form the basis of the second STOP/GO decision.
1. IOC consider an RCT unfeasible. DECISION: Do not 
proceed to main RCT.
2. IOC consider an RCT feasible. DECISION: Provide re-
port to funder with recommendation of IOC, in order 
for a final decision to be made on progression to the 
full RCT.
Patient and public involvement
Our protocol was developed in consultation with a patient 
and public involvement (PPI) group referred to as the 
Clinical Research Ambassador Group, based at University 
Hospital NHS Foundation Trust. One of the coapplicants 
is a patient with IBD and also Chairperson for the West 
Midlands Group of Crohn’s and Colitis UK (CCUK) and 
she helped develop the proposal. The PPI has strong 
links with CCUK and this will significantly aid dissemina-
tion of findings nationally to patients, relatives and health 
professionals.
As we are aware that acceptability of FMT in UC has 
not been extensively studied, we designed the pilot study 
to investigate patient acceptability of the therapy by 
regular questionnaires, individual interviews and group 
discussions. We conducted a survey of our own IBD 
patients from the outpatient department at University 
Hospital Birmingham. Of the 74 patients surveyed, the 
vast majority of patients would accept FMT as a treatment 
for IBD and over 80% would consider involvement in a 
trial of FMT in IBD. Qualitative interviews with patients 
will be conducted at baseline and at the end of the study 
and these findings will feed into the discussions regarding 
progression to a full- scale RCT. Patients recruited to the 
study will not necessarily directly assist with the recruit-
ment of other patients.
Ethics and dissemination
The trial will be performed in accordance with the recom-
mendations guiding physicians in biomedical research 
involving human subjects, adopted by the 18th World 
Medical Association General Assembly, Helsinki, Finland, 
June 1964, amended at the 48th World Medical Associa-
tion General Assembly, Somerset West, Republic of South 
Africa, October 1996.
The trial will be conducted in accordance with the 
Research Governance Framework for Health and Social 
Care, the applicable UK Statutory Instruments (which 
include the Medicines for Human Use Clinical Trials 
2004 and subsequent amendments and the General 
Data Protection Regulation (GDPR) (EU) 2016/679 and 
Human Tissue Act 2008) and Guidelines for Good Clin-
ical Practice. This trial will be carried out under a Clinical 
Trial Authorisation in accordance with the Medicines for 
Human Use Clinical Trials regulations.
Publication policy
At the end of the study, a meeting will be held to allow 
discussion of the main results among the collaborators 
prior to publication. The success of the study will depend 
entirely on the wholehearted collaboration of a large 
number of doctors, nurses and others. For this reason, 
the chief credit for the main results will be given not only 
to the central supervisory committees and/or organisers, 
but to all those who have collaborated in the trial.
The findings will be reported at national and interna-
tional gastroenterology meetings and published in peer- 
reviewed journals.
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